Skip to content

Register for Langerhans Cell Histiocytosis in Children in Germany (LCH REG DE 2025)

Register for Langerhans Cell Histiocytosis in Children in Germany (LCH REG DE 2025) - LCH REG DE 2025

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00040100
Enrollment
800
Registered
2026-04-28
Start date
2026-05-08
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Langerhanscell-Histiozytosis (LCH) C96.0 C96.5 C96.6

Interventions

Group 1: Survey on epidemiological data, clinical presentations, disease progression, follow-up care, and complications associated with the disease. The data are collected prospectively.

Sponsors

Klinik für Kinder-und Jugendmedizin, Schwerpunkt Onkologie, Hämatologie und Hämostaseologie, Universitätsmedizin Frankfurt, Goethe-Universität Frankfurt
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: The cohort is defined as follows: • Patients with histologically confirmed Langerhans cell histiocytosis (LCH) • Exception: Patients with diabetes insipidus not caused by a germ cell tumor (“strong suspicion of LCH”); this specific patient population may be included in the registry despite the lack of histological confirmation of LCH The following inclusion criteria are defined: • Age 0–18 years • Consent from legal guardians and patients (as appropriate for age) is available

Exclusion criteria

Exclusion criteria: The following exclusion criteria have been defined: • Age >18 years at initial enrollment • No histological confirmation of LCH (exception: diabetes insipidus of unknown cause; see above) • No written informed consent on file

Design outcomes

Primary

MeasureTime frame
1. Age at onset, gender, medical history 2. Mutational status of LCH cells 3. Pattern of disease involvement (monosystemic, multisystemic) 4. Organ manifestation(s) 5. Involvement of high-risk organs (liver, spleen, hematopoietic system) and “special sites” (specific craniofacial bones) 6. Concomitant issues such as hormonal deficiencies, orthopedic problems 7. Treatment(s)

Secondary

MeasureTime frame
Follow-up care: normal findings/recurrence/persistent issues (e.g., hormone replacement therapy)

Countries

Germany

Contacts

Public ContactAnke Barnbrock

Klinik für Kinder-und Jugendmedizin, Schwerpunkt Onkologie, Hämatologie und Hämostaseologie, Universitätsmedizin Frankfurt, Goethe-Universität Frankfurt

anke.barnbrock@unimedizin-ffm.de+496963016489

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026